AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20178624
Drug: Patient-centered quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered quality improvement interventions (communication skills training and care management focused on explanatory models, socio-cultural barriers, and treatment preferences)
Trial: 20180805
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg single dose followed by continuous 5 mg twice-daily dosing
Trial: 20180805
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice-daily
Trial: 20181282
Drug: Latanoprost once
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost once daily (evening)
Trial: 20184783
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg once daily for 6 weeks
Trial: 20184807
Drug: Antipsychotic-naive first-episode
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antipsychotic-naive first-episode schizophrenia patients
Trial: 20187924
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 to 60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 52 weeks
Trial: 20188202
Drug: NK cell-enriched
RxNorm normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cell-enriched donor lymphocyte infusions (DLIs)
Trial: 20189159
Drug: 1% mecamylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mecamylamine topically twice daily for 12 weeks
Trial: 20190585
Drug: Enhanced vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced vaccine education intervention with pictures and application vignettes and enhanced risk-reduction counseling (3 one-on-one counseling sessions)
Trial: 20191499
Drug: DHEA substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA substitution (50 mg/day)
Trial: 20194866
Drug: Ofatumumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (300 mg for dose 1; 2000 mg for doses 2 to 12) administered as eight weekly infusions followed by four monthly infusions over 24 weeks
Trial: 20200024
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg daily on 4-week cycles
Trial: 20203173
Drug: Sunitinib (SU)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (SU) 37.5 mg daily
Trial: 20205741
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise (twice weekly for 12 weeks)
Trial: 20205864
Drug: Weekly short-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly short-time recalls for EBF at week 6
Trial: 20205864
Drug: Weekly short-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly short-time recalls for PBF at week 6
Trial: 20205864
Drug: Weekly short-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly short-time recalls for EBF at week 12
Trial: 20205864
Drug: Weekly short-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly short-time recalls for PBF at week 12
Trial: 20206940
Drug: Intravenous ECG
RxNorm normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ECG monitoring during PICC insertion
Trial: 20210645
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV) prime at week 0 followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) boost at week 4
Trial: 20211302
Drug: Any beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any beta-blocker for patients with LVSD
Trial: 20211302
Drug: Evidence-based beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based beta-blocker for patients with LVSD
Trial: 20211302
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for patients with atrial fibrillation
Trial: 20211302
Drug: Aldosterone antagonist
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone antagonist for patients with LVSD
Trial: 20211560
Drug: Oral masitinib
RxNorm normalized name: axitinib Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral masitinib at 7.5mg/kg/d
Trial: 20214798
Drug: Additional parenteral
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional parenteral nutrition (APN)
Trial: 20216101
Drug: Food allergy
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [FOOD ALLERGY FORMULA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food allergy screening (skin prick, atopy patch, serum-specific IgE, IgG, IgG4 testing)
Trial: 20216101
Drug: Skin prick,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin prick, atopy patch, and serum-specific testing
Trial: 20220062
Drug: Dynamic contrast-enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before treatment (day 0) and on day 7 after induction chemotherapy
Trial: 20221623
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with verteporfin alone (PDT)
Trial: 20221623
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy combined with intravitreal bevacizumab (COMB)
Trial: 20222977
Drug: Canfosfamide plus
RxNorm normalized name: Canfosfamide
DrugBank: Canfosfamide (DB04972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canfosfamide plus pegylated liposomal doxorubicin (PLD) at 960/50 mg/m2
Trial: 20225992
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous C.E.R.A.
Trial: 20226028
Drug: Heavy ion
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy ion therapy (HIT) with a target dose of 60-66 Gy E, including 45 Gy PT and a carbon ion boost of 15-21 Gy E, administered weekly in fractions of 5-6 x 3 Gy E
Trial: 20230209
Drug: IV esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV esomeprazole 40 mg twice daily for 48 hours (can continue for another 24 hours if no prepyloric enteral feedings planned)
Trial: 20230418
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment of acute pulmonary embolism with low NT-proBNP levels (< 500 pg mL(-1)).
Trial: 20231206
Drug: No immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunosuppressive therapy
Trial: 20233136
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow cells (BMSC)
Trial: 20234331
Drug: PCV-7 vaccine
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV-7 vaccine administered at 2, 4, and 6 months after birth
Trial: 20234331
Drug: PCV-7 vaccine
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV-7 vaccine administered
Trial: 20236340
Drug: Menstrual migraine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menstrual migraine treatment episodes
Trial: 20236340
Drug: Nonmenstrual migraine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmenstrual migraine treatment episodes
Trial: 20236700
Drug: AHU377 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHU377 200 mg
Trial: 20237066
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K concentration in subcutaneous adipose tissue
Trial: 20298563
Drug: Patient activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient activation intervention (letter to discuss thiazide diuretics)
Trial: 20299511
Drug: Velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velaglucerase alfa (60 U/kg per infusion) during phase 1/2
Trial: 20299511
Drug: Velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velaglucerase alfa (30 U/kg per infusion) during extension study
Trial: 20307284
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 fatty acid supplement (exact dosage not specified)
Trial: 20307398
Drug: Controlled-release alpha
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release alpha lipoic acid (CRLA) 600 mg twice daily for 16 weeks
Trial: 20338746
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy followed by low intensity 'maintenance' chemotherapy (6-drug regimen with local therapy of surgery and/or radiotherapy followed by 9 courses of vincristine, actinomycin D and cyclophosphamide (VAC)) for SRG.
Trial: 20338746
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose monotherapy followed by low dose maintenance chemotherapy (VAC) for PRG.
Trial: 20339536
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day simvastatin for 6 weeks
Trial: 20339536
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day pravastatin for 24 weeks
Trial: 20339536
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day atorvastatin for 8 weeks
Trial: 20346127
Drug: Latanoprost/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/timolol fixed combination (FC)
Trial: 20350136
Drug: Intermediate CYP2D6
RxNorm normalized name: PREVOTELLA INTERMEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate CYP2D6 metabolism (0.5 SGD)
Trial: 20350189
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment during pregnancy (IPTp)
Trial: 20350192
Drug: Artemisinin derivatives
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin derivatives treatment
Trial: 20354809
Drug: Chronic InterStim
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic InterStim Therapy device (Medtronic) implantation
Trial: 20363090
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) 380 mg, intramuscular, with monthly medical management (MM)
Trial: 20363090
Drug: Monthly medical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly medical management (MM)
Trial: 20364383
Drug: Intraepidermal injection
RxNorm normalized name: HYALURONIC ACID 2.5 g INTRAEPIDERMAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraepidermal injection of autologous dissociated epidermal cell suspension
Trial: 20368313
Drug: Glomerular filtration
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glomerular filtration rate (GFR) reference values measured at inclusion and weekly for the first month using 12-hour urine specimens.
Trial: 20368434
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m² i.v. over 1 h on days 1 to 10)
Trial: 20369375
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg/day
Trial: 20372873
Drug: Low-dose growth
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 weeks
Trial: 20372873
Drug: Low-dose growth
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 48 weeks
Trial: 20372873
Drug: Low-dose growth
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 and 48 weeks
Trial: 20372873
Drug: Low-dose growth
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day)
Trial: 20378407
Drug: Vorinostat 300
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 300 mg once daily
Trial: 20378407
Drug: Vorinostat 400
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 400 mg once daily
Trial: 20378407
Drug: Vorinostat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (various doses)
Trial: 20378616
Drug: Ganirelix (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix (GnRH antagonist)
Trial: 20378730
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) - 6 months of open-label, daily, self-administered INH.
Trial: 20378730
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) - received by 480 participants.
Trial: 20378730
Drug: Age greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age greater than 35 years and presence of hepatitis B virus core antibody.
Trial: 20378927
Drug: Modified slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified slow-release oral testosterone
Trial: 20378927
Drug: Immediate-release oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oral testosterone
Trial: 20378927
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone with finasteride
Trial: 20378927
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone without finasteride
Trial: 20384395
Drug: Propiverine 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 5, 10 and 15 mg twice daily for 14 days
Trial: 20385792
Drug: Lenalidomide-bortezomib-dexamethasone combination
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide-bortezomib-dexamethasone combination therapy
Trial: 20385942
Drug: Weekly examinations
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly examinations for type 2 ROP
Trial: 20386074
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) therapy (2 g/kg)
Trial: 20386909
Drug: MK-0457 (24-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0457 (24-h continuous intravenous infusion at 64 mg/m(2)/h every 21 days)
Trial: 20386909
Drug: MK-0457 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0457 (100 mg oral dose administered 48 h prior to CIV infusion)
Trial: 20386909
Drug: MK-0457 (24-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0457 (24-h continuous intravenous infusion)
Trial: 20390419
Drug: TSU-68 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSU-68 at a dose of 200 mg bid
Trial: 20391423
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 400 mg/kg every 3 weeks from week 12 to week 24 of gestation
Trial: 20393132
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of mitoxantrone for the second consolidation course for low- and intermediate-risk patients.
Trial: 20394026
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion (CII) with oral intake
Trial: 20398925
Drug: MDV3100 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 30 mg
Trial: 20398925
Drug: MDV3100 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 60 mg
Trial: 20398925
Drug: MDV3100 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 240 mg
Trial: 20398925
Drug: MDV3100 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 (various doses)
Trial: 20398925
Drug: MDV3100 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 (60 mg to 480 mg)
Trial: 20398959
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then maintenance therapy twice per week for 12 weeks if clear or almost clear (cohort B)
Trial: 20398959
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 24 weeks (cohort A)
Trial: 20398959
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then returned to daily dosing after relapse during maintenance (cohort C)
Trial: 20400682
Drug: WT1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1 peptide vaccine (4 peptides, 200 microg each) with immune adjuvants, administered over 12 weeks (6 vaccinations)
Trial: 20400682
Drug: WT1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1 peptide vaccine
Trial: 20400762
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) for 48 h
Trial: 20403857
Drug: Drug-induced sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced sleep endoscopy with intravenous propofol infusion
Trial: 20408846
Drug: ofatumumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ofatumumab (4 weekly infusions)
Trial: 20410100
Drug: SNPs in
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNPs in tumor necrosis factor receptor superfamily member 10b (TNFRSF10B)
Trial: 20412178
Drug: Rifaximin 600
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 600 mg/d for 14 days
Trial: 20413029
Drug: Combined HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HF device diagnostics (positive criteria: long atrial fibrillation duration, rapid ventricular rate during atrial fibrillation, high fluid index, low patient activity, abnormal autonomics, notable device therapy, or very high fluid index)
Trial: 20413733
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment with LDLR haplotype 5 (LDLR L5) in blacks
Trial: 20413733
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment with combined LDLR L5 and HMGCR haplotypes in blacks
Trial: 20413733
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment measuring LDL receptor surface expression
Trial: 20418798
Drug: CD4 count
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD4 count criteria for initiating antiretroviral therapy
Trial: 20420675
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to organic or inorganic allergenic or irritant compounds
Trial: 20421452
Drug: Deferasirox (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (30 to 40 mg/kg per day)